Hematological Malignancies

First page Previous page 339 Next page Last page

Overview of talk 1. Review clinical data on management of early stage HL – Should combined modality treatment still be the standard approach ? 2. Recent progress in using FDG PET to guide therapy and delivery of RT in HL - Are we ready to make treatments decisions based on FDG-PET to potentially omit RT ?

Made with